PMID- 22901172
OWN - NLM
STAT- MEDLINE
DCOM- 20130122
LR  - 20221207
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Linking)
VI  - 13
IP  - 5
DP  - 2012
TI  - Significance of human telomerase RNA gene amplification detection for cervical 
      cancer screening.
PG  - 2063-8
AB  - AIM: Liquid-based cytology is the most often used method for cervical cancer 
      screening, but it is relatively insensitive and frequently gives equivocal 
      results. Used as a complementary procedure, the high-risk human papillomavirus 
      (HPV) DNA test is highly sensitive but not very specific. The human telomerase 
      RNA gene (TERC) is the most often amplified oncogene that is observed in cervical 
      precancerous lesions. We assessed genomic amplification of TERC in liquid-based 
      cytological specimens to explore the optimal strategy of using this for cervical 
      cancer screening. METHODS: Six hundred and seventy-one residual cytological 
      specimens were obtained from outpatients aged 25 to 64 years. The specimens were 
      evaluated by the Digene Hybrid Capture 2 (HC2) HPV DNA test and fluorescence in 
      situ hybridization (FISH) with a chromosome probe to TERC (3q26). Colposcopic 
      examination and histological evaluation were performed where indicated. RESULTS: 
      The TERC positive rate was higher in the CIN2+ (CIN2, CIN3 and SCC) group than in 
      the normal and CIN 1 groups (90.0% vs. 10.4%, p<0.01). In comparison with the HC2 
      HPV DNA test, the TERC amplification test had lower sensitivity but higher 
      specificity (90.0% vs. 100.0%, 89.6% vs. 44.0%, respectively). TERC amplification 
      test used in conjunction with the HC2 HPV DNA test showed a combination of 90.0% 
      sensitivity and 92.2% specificity. CONCLUSION: The TERC amplification test can be 
      used to diagnose cervical precancerous lesions. TERC and HPV DNA co-testing shows 
      an optimal combination of sensitivity and specificity for cervical cancer 
      screening.
FAU - Chen, Shao-Min
AU  - Chen SM
AD  - Department of Obstetrics and Gynecology, Weifang People's Hospital, Weifang, 
      China E-mail : zhangyouzhong@sdu.edu.cn.
FAU - Lin, Wei
AU  - Lin W
FAU - Liu, Xin
AU  - Liu X
FAU - Zhang, You-Zhong
AU  - Zhang YZ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (telomerase RNA)
RN  - 63231-63-0 (RNA)
RN  - EC 2.7.7.49 (TERT protein, human)
RN  - EC 2.7.7.49 (Telomerase)
SB  - IM
MH  - Adult
MH  - Carcinoma, Squamous Cell/diagnosis/genetics/virology
MH  - Cervix Uteri/metabolism/virology
MH  - *Cytodiagnosis
MH  - *Early Detection of Cancer
MH  - Female
MH  - *Gene Amplification
MH  - Human Papillomavirus DNA Tests
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - RNA
MH  - RNA, Long Noncoding/*genetics
MH  - Risk Factors
MH  - Telomerase/*genetics
MH  - Uterine Cervical Dysplasia/diagnosis/genetics/virology
MH  - Uterine Cervical Neoplasms/*diagnosis/*genetics/virology
EDAT- 2012/08/21 06:00
MHDA- 2013/01/23 06:00
CRDT- 2012/08/21 06:00
PHST- 2012/08/21 06:00 [entrez]
PHST- 2012/08/21 06:00 [pubmed]
PHST- 2013/01/23 06:00 [medline]
AID - 10.7314/apjcp.2012.13.5.2063 [doi]
PST - ppublish
SO  - Asian Pac J Cancer Prev. 2012;13(5):2063-8. doi: 10.7314/apjcp.2012.13.5.2063.